Our recombinant protein and antibody capabilities include mammalian cell line generation, production, purification and analysis of recombinant proteins and antibodies manufactured in mammalian systems.
Protein and antibody capabilities
Here at Batavia Biosciences, we generate protein and antibody products as well as perform process development and scale-up of such products in our Woburn facility (MA, USA). Clinical manufacturing of all products is performed in our GMP facility located in the Netherlands. Batavia Biosciences offers unique technologies to increase protein and antibody product yields, decrease process development time, and improve product stability. In general, our strengths include vector construction, stable mammalian cell line generation, small- and large-scale transient production, upstream and downstream process development and scale-up, medium selection, feed strategy optimization, analytical development, product characterization and cGMP manufacturing. Our comprehensive expertise allows us to deliver a complete package comprising of purified product together with all relevant protocols and pivotal biochemical and analytical characterization data.
Proteins and antibodies track record
We have successfully delivered a diverse range of biosimilars including growth factors, fertility hormones, enzymes, anti-cancer fusion proteins, clotting factors, antibodies, antibody fragments, viral proteins and antigenic proteins. For instance, in collaboration with Prof. James Crowe (Pediatrics & Pathology, Microbiology & Immunology Department, Vanderbilt Vaccine Center, Nashville) we have worked on the generation of CHO cell lines expressing potent virus-neutralizing antibodies. Additionally, for COPro Biotech, we have used our STEP® technology to develop a stable biosimilar producer cell line.
Proteins & antibodies technologies
STEP® technology
To enable the rapid generation of stable protein or antibody expressing CHO cell lines, we have developed an affordable and complete package of services and technologies. Our approach provides significant more product per cell compared to commercially available benchmarks.
SCOUT® technology
SCOUT® technology is an effective tool for Design-of-Experiments (DoE) approaches as it uses a miniaturized production and purification platform to quickly develop multivariate processes.
Process development
We develop scalable, robust and GMP-compliant manufacturing processes for viral vectors.
Upstream process development
We deliver scalable and robust GMP-compliant purification processes for recombinant proteins.
Downstream process development
We deliver scalable and robust GMP-compliant purification processes for recombinant proteins.
Analytical development
We support the development of all the required product-specific release and stability-determining assays for your recombinant protein.
In silico cost modeling
We often perform in silico cost modeling of manufacturing processes for recombinant protein products.
Related resources
Written by expert: Gert, Associate Director Assays The matrix effect is the effect on an analytical assay caused by all other components of the sample except the specific compound (analyte)…
Written by expert: Wilfried, Director of Science and Innovation For protein-based biopharmaceuticals, product yield from mammalian cell lines is a critical economic driver. Naturally, increased specific productivity – microgram product…
Written by expert: Alfred, Global Technical Sales Director The selection of stable protein producing cell lines is tedious, time consuming and capital intensive. The introduction of various high-throughput cell screening…
Written by Expert: Wilfried, Director Science & Innovation. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch…
